☆ 4.8 Article

Engineered a dual-targeting HA-TPP/A nanoparticle for combination therapy against KRAS-TP53 co-mutation in gastrointestinal cancers

BIOACTIVE MATERIALS (2024)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Gastroenterology & Hepatology

Updated epidemiology of gastrointestinal cancers in East Asia

Junjie Huang et al.

Summary: Globally, gastrointestinal cancers account for over one-fourth of all cancer incidence and one-third of cancer-related mortality. East Asia has the highest burden of gastrointestinal cancers, including stomach, liver, oesophageal, and gallbladder cancers, which is attributed to population growth, aging, and westernization of lifestyles. The increasing incidence of young-onset colorectal cancer is also observed in East Asia. To effectively reduce the burden of gastrointestinal cancers in this region, efforts should be made to modify unhealthy lifestyles, promote vaccination against hepatitis virus, control infections, increase colorectal cancer screening, enhance early cancer detection, and improve cancer survivorship through organized rehabilitation programs.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Drugging p53 in cancer: one protein, many targets

Ori Hassin et al.

Summary: Mutations in the TP53 gene are common in cancer, but restoring p53 functionality has been considered impossible for a long time. However, recent years have seen promising developments in p53-based therapy, including improved strategies and novel approaches. Small molecules that protect or restore p53 function are gaining interest, along with tailored drugs for specific p53 mutants. Additionally, gene therapy and immunotherapy are being reconsidered. However, significant challenges remain.

NATURE REVIEWS DRUG DISCOVERY (2023)

添加到收藏夹

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Oncology

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

Marwan G. Fakih et al.

Summary: Sotorasib, a specific inhibitor of KRAS(G12C) protein, showed modest anti-tumour activity and manageable safety in heavily pretreated patients with colorectal cancer in a phase 2 trial. The overall response rate of 9.7% did not reach the benchmark, but sotorasib is being evaluated in combination with other therapeutics to enhance potential activity and address potential resistance mechanisms.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

The complexity of p53-mediated metabolic regulation in tumor suppression

Yanqing Liu et al.

Summary: The metabolic regulation of p53 in tumor suppression is complex and diverse. It inhibits tumor development through regulating glucose, lipid, amino acid, nucleotide, iron metabolism, and ROS production.

SEMINARS IN CANCER BIOLOGY (2022)

添加到收藏夹

Article Chemistry, Multidisciplinary

Smart PdH@MnO2 Yolk-Shell Nanostructures for Spatiotemporally Synchronous Targeted Hydrogen Delivery and Oxygen-Elevated Phototherapy of Melanoma

Wandong Wang et al.

Summary: Hydrogen therapy is an emerging therapeutic strategy in anticancer medicine, but the challenges of stable hydrogen storage and efficient delivery hinder its development. In this study, a smart yolk-shell nanoplatform was designed to overcome these challenges and enhance the efficacy of photodynamic therapy through hydrogen release, increased reactive oxygen species generation, and ameliorated hypoxic conditions.

ACS NANO (2022)

添加到收藏夹

Article Engineering, Biomedical

length Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials

Meimei Wang et al.

Summary: This article investigates the degradation of mutant p53 proteins by AIE-Mit-TPP and the impact of autophagy on this degradation. The results show that AIE-Mit-TPP induces proteasomal degradation of mutp53 proteins and inhibits their gain-of-function properties, while also causing mitochondrial damage and autophagy. Inhibition of autophagy further enhances the degradation of mutp53 by AIE-Mit-TPP and suppresses cell proliferation and migration, leading to cell cycle arrest and cell death. Therefore, AIE-Mit-TPP has an inhibitory effect on the growth of p53-mutated tumors.

ACTA BIOMATERIALIA (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer

Jashodeep Datta et al.

Summary: Co-occurrent KRAS and TP53 mutations are common in patients with pancreatic ductal adenocarcinoma (PDAC) and are associated with worse survival. These mutations lead to innate immune enrichment and CD8(+) T-cell exclusion, as well as affecting transcriptomes and cell migration in the tumor microenvironment. These molecular characteristics can predict chemoresistance and overall survival in patients with metastatic PDAC.

ONCOGENE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer

Chi Chun Wong et al.

Summary: The cholesterol-uptake regulator PCSK9 drives tumourigenesis and is a therapeutic target in KRAS-mutant colorectal cancer.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Oncology

Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition

Jiang Li et al.

Summary: The study demonstrates the importance of mitochondrial fission in macrophages for phagocytosis induced by therapeutic antibodies, with GFPT2 identified as an inhibitor of the process. This finding contributes to improving antibody therapy efficacy and providing new mechanistic insights into the phase transition of the phagocytic machinery.

NATURE CANCER (2022)

添加到收藏夹

Article Cell Biology

A high-throughput screening identifies ZNF418 as a novel regulator of the ubiquitin-proteasome system and autophagy-lysosomal pathway

Sonia R. Singh et al.

Summary: The study revealed that ZNF418 activates the ALP, inhibits the UPS, and regulates genes associated with cardiomyocyte structure and function. RNA-seq analysis showed that ZNF418 also plays a role in regulating genes involved in cardiac development and/or hypertrophy.

AUTOPHAGY (2021)

添加到收藏夹

Article Engineering, Biomedical

Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy

Boyi Niu et al.

Summary: Glutathione (GSH) plays a crucial role in cellular antioxidative system, particularly in cancer cells, where a high level of GSH is essential for scavenging ROS and detoxifying xenobiotics. Depletion of GSH has been shown to enhance the efficacy of various therapies such as ROS-based therapy, ferroptosis, and chemotherapy. This review comprehensively discusses the importance of GSH depletion in cancer therapy and various strategies employed to achieve it.

BIOMATERIALS (2021)

添加到收藏夹

Review Chemistry, Multidisciplinary

The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors

Mukaddes Izci et al.

Summary: Research has shown that despite efforts to utilize the EPR effect for enhanced delivery of nanomaterials to solid tumors, the results are still poor. Furthermore, some studies question the role of the EPR effect, suggesting that nanomaterials may enter tumors through active mechanisms rather than through endothelial gaps.

CHEMICAL REVIEWS (2021)

添加到收藏夹

Article Nanoscience & Nanotechnology

A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells

Shiyang Shen et al.

Summary: This study presents a nanoparticle-based strategy for killing CSCs in tumors by inducing CSC differentiation with all-trans retinoic acid release under hypoxic conditions and triggering cell death with camptothecin release in response to increasing reactive oxygen species levels in differentiating CSCs.

NATURE NANOTECHNOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Gongmin Zhu et al.

Summary: KRAS is a commonly mutated oncogene in colorectal cancer, leading to aberrant activation of the KRAS protein and stimulation of downstream signaling pathways, resulting in cell proliferation and survival, ultimately leading to tumorigenesis. Patients with KRAS mutations in CRC have poor prognosis.

MOLECULAR CANCER (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Diverse alterations associated with resistance to KRAS(G12C) inhibition

Yulei Zhao et al.

Summary: Resistance to KRAS(G12C) inhibitors demonstrates a heterogeneous pattern with multiple subclonal events emerging during treatment. Co-targeting of ERK signaling intermediates can enhance the antiproliferative effect of G12C inhibitor treatment in models with acquired RAS or BRAF mutations.

NATURE (2021)

添加到收藏夹

Review Oncology

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines

A. Grothey et al.

Summary: Colorectal cancer remains a leading cause of cancer-related deaths globally, with the mutation in the BRAF gene, particularly the V600E substitution, affecting 10% of metastatic CRC patients and indicating a poor prognosis. Recent advancements in combination therapies targeting the MAPK pathway have shown promising results in treating BRAF V600E-mutated mCRC patients, offering new hope in the management of this subtype of cancer.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Engineering, Biomedical

Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8

Yunjiao Zhang et al.

Summary: The pH-responsive zeolitic imidazolate framework-8 (ZIF-8) has shown to promote ubiquitination-mediated and glutathionylation-dependent degradation of various mutp53 proteins, including hot-spot mutp53, offering a promising approach for the treatment of p53-mutated cancer.

BIOMATERIALS (2021)

添加到收藏夹

Article Oncology

Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis

Michael P. Kim et al.

Summary: The study found that oncogenic KRAS effectors activate CREB1 to interact with mutant p53, promoting PDAC metastasis. Inhibiting CREB1 can reduce the expression of FOXA1 and beta-catenin, slowing down PDAC metastasis.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

Clinical Acquired Resistance to KRASG12C Inhibition through a novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation

Noritaka Tanaka et al.

Summary: This study described a patient with KRAS(G12C) non-small cell lung cancer who developed polyclonal acquired resistance to MRTX849 treatment. The research identified 10 heterogeneous resistance alterations that converged to reactivate the RAS-MAPK signaling pathway. Additionally, a novel KRAS(Y96D) mutation affecting key protein-drug interactions and driving resistance was discovered.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Pancreatic Tumor Microenvironment Factor Promotes Cancer Stemness via SPP1-CD44 Axis

Palanisamy Nallasamy et al.

Summary: The study revealed that CAFs promote stemness enrichment in PC through the osteopontin/secreted phosphoprotein 1-CD44 axis. Long-term treatment of PC cells with CAF-CM resulted in increased stemness characteristics, indicated by significantly higher levels of CSC markers and enhanced tumorsphere formation.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Acquired Resistance to KRASG12C Inhibition in Cancer

M. M. Awad et al.

Summary: A study of 38 patients with KRAS(G12C)-mutant cancers treated with adagrasib revealed diverse mechanisms of acquired resistance in 45% of them, including various mutations and bypass mechanisms. New therapeutic strategies are needed to overcome this drug resistance.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer

Jashodeep Datta et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Review Oncology

Targeting the MAPK Pathway in KRAS-Driven Tumors

Matthias Drosten et al.

CANCER CELL (2020)

添加到收藏夹

Article Oncology

KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population

Marta Schirripa et al.

CLINICAL COLORECTAL CANCER (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties

Mizuho Nakayama et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Oncology

Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer

Luisa F. Escobar-Hoyos et al.

CANCER CELL (2020)

添加到收藏夹

Article Chemistry, Multidisciplinary

Enhancing Chemotherapy of p53-Mutated Cancer through Ubiquitination-Dependent Proteasomal Degradation of Mutant p53 Proteins by Engineered ZnFe-4 Nanoparticles

Jieying Qian et al.

ADVANCED FUNCTIONAL MATERIALS (2020)

添加到收藏夹

Review Cell Biology

Gain-of-function mutant p53 in cancer progression and therapy

Cen Zhang et al.

JOURNAL OF MOLECULAR CELL BIOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation

Jinchul Kim et al.

CANCER CELL (2019)

添加到收藏夹

Article Cell Biology

Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis

Eleonora Ingallina et al.

NATURE CELL BIOLOGY (2018)

添加到收藏夹

Review Oncology

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Kanaga Sabapathy et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Matthew R. Janes et al.

CELL (2018)

添加到收藏夹

Review Oncology

Therapeutic strategies to target RAS-mutant cancers

Meagan B. Ryan et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Targeting mutant p53 for efficient cancer therapy

Vladimir J. N. Bykov et al.

NATURE REVIEWS CANCER (2018)

添加到收藏夹

Review Chemistry, Multidisciplinary

Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications

Jacek Zielonka et al.

CHEMICAL REVIEWS (2017)

添加到收藏夹

Article Oncology

Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer

Robert P. Jones et al.

BRITISH JOURNAL OF CANCER (2017)

添加到收藏夹

Article Oncology

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

D. P. Modest et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Cell Biology

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway

Alejandro Parrales et al.

NATURE CELL BIOLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

Jiajun Zhu et al.

NATURE (2015)

添加到收藏夹

Article Biology

BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function

Xuetian Yue et al.

ELIFE (2015)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Drugging the undruggable RAS: Mission Possible?

Adrienne D. Cox et al.

NATURE REVIEWS DRUG DISCOVERY (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells

Oliver D. K. Maddocks et al.

NATURE (2013)

添加到收藏夹

Review Multidisciplinary Sciences

Cancer Genome Landscapes

Bert Vogelstein et al.

SCIENCE (2013)

添加到收藏夹

Article Neurosciences

Distinct Roles In Vivo for the Ubiquitin-Proteasome System and the Autophagy-Lysosomal Pathway in the Degradation of α-Synuclein

Darius Ebrahimi-Fakhari et al.

JOURNAL OF NEUROSCIENCE (2011)

添加到收藏夹

Article Oncology

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Rafael G. Amado et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹

Article Oncology

Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics

Yili Yang et al.

CANCER RESEARCH (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.